Peptide-loaded nanoparticles and radionuclide imaging for individualized treatment of myocardial ischemia.
暂无分享,去创建一个
Chang-Moon Lee | Myung-Hee Sohn | Hwan-Jeong Jeong | M. Sohn | Hyosook Hwang | Jeong-Hui Kwon | P. Oh | T. Lee | Kyung-Suk Na | Chang-Moon Lee | Hwan-Seok Jeong | S. Lim | Hyosook Hwang | Jeongll Kwon | Phil-Sun Oh | Tai-Kyoung Lee | Kyung-Suk Na | Hwan-Seok Jeong | Seok Tae Lim | Hwan-Jeong Jeong | Chang‐Moon Lee
[1] Hong Yuan,et al. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[2] M. Simons,et al. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. , 2005, Cardiovascular research.
[3] R. Hendel,et al. Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. , 1995, Circulation.
[4] Wadih Arap,et al. From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway , 2010, Proceedings of the National Academy of Sciences.
[5] Lorenzo Deveza,et al. Therapeutic Angiogenesis for Treating Cardiovascular Diseases , 2012, Theranostics.
[6] F. Sellke,et al. Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.
[7] R. Hendel,et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. , 2001, American heart journal.
[8] R. Hendel,et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. , 2000, Circulation.
[9] X. Chen,et al. Uptake of oleoyl-chitosan nanoparticles by A549 cells. , 2008, Nanomedicine : nanotechnology, biology, and medicine.
[10] M. Garcia‐Fuentes,et al. Chitosan-based drug nanocarriers: where do we stand? , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[11] J. Pearlman,et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. , 1996, The American journal of physiology.
[12] David J Mooney,et al. Effects of VEGF temporal and spatial presentation on angiogenesis. , 2010, Biomaterials.
[13] L. Morbidelli,et al. Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. , 2012, Biochemical pharmacology.
[14] D. Mooney,et al. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. , 2011, Nano letters.
[15] Petra Krystek,et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.
[16] J. Leor,et al. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. , 2011, Biomaterials.
[17] J L Cleland,et al. Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[18] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[19] S. Epstein,et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. , 1994, Circulation.
[20] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] Larry Kedes,et al. Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. , 2005, Cardiovascular research.
[22] A. D. de Vos,et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.
[23] M. Martín-Martínez,et al. Parallel solid-phase synthesis of a small library of linear and hydrocarbon-bridged analogues of VEGF(81-91): potential biological tools for studying the VEGF/VEGFR-1 interaction. , 2011, Bioorganic & medicinal chemistry.
[24] K. Christman,et al. Biomaterials for the treatment of myocardial infarction: a 5-year update. , 2011, Journal of the American College of Cardiology.
[25] S. Epstein,et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. , 1996, Circulation.
[26] Brian H Annex,et al. The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .
[27] G. Dellgren,et al. Angiogenic and cardiac functional effects of dual gene transfer of VEGF-A165 and PDGF-BB after myocardial infarction. , 2004, Biochemical and biophysical research communications.
[28] M. Martín-Martínez,et al. Disulfide and amide-bridged cyclic peptide analogues of the VEGF₈₁₋₉₁ fragment: synthesis, conformational analysis and biological evaluation. , 2011, Bioorganic & medicinal chemistry.
[29] J. Isner,et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.
[30] Brian H Annex,et al. A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans , 2002, Clinical pharmacology and therapeutics.
[31] L. Zentilin,et al. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. , 2009, Cardiovascular research.
[32] R. Kloner,et al. Improving regenerating potential of the heart after myocardial infarction: factor-based approach. , 2010, Life sciences.